Title
Leflunomide and methotrexate reduce levels of activated matrix metalloproteinases in complexes with α2 macroglobulin in serum of rheumatoid arthritis patients
Author
Tchetverikov, I.
Kraan, M.C.
van El, B.
Hanemaaijer, R.
de Groot, J.
Huizinga, T.W.J.
Publication year
2008
Abstract
Objective: To analyse the effects of leflunomide and methotrexate treatment on matrix metalloproteinase (MMP) activity levels in a2 macroglobulin/MMP (α2M/MMP) complexes in the systemic circulation of rheumatoid arthritis (RA) patients. Methods: A total of 102 RA patients from a prospective, double-blind, randomised clinical trial comparing leflunomide and methotrexate were selected; clinical data and blood samples were collected at baseline, at 4 months and at 1 year. Serum MMP activity levels in α2M were quantified using low molecular weight fluorogenic substrates, indicating the proportion of activated MMPs that were not inhibited by specific tissue inhibitors of MMP (TIMP). Results: Patients had active disease as shown by high disease activity score (DAS, mean of 6.9 and 7.0 for methotrexate and leflunomide patients respectively), which was reduced over the study period (4.2 and 5.2 respectively, p
Subject
Biomedical Research
alpha 2 macroglobulin
C reactive protein
leflunomide
matrix metalloproteinase
methotrexate
teriflunomide
tissue inhibitor of metalloproteinase 1
analysis
blood sampling
clinical study
complex formation
controlled study
disease activity
drug activity
drug dose increase
drug effect
drug efficacy
drug exposure
loading drug dose
major clinical study
priority journal
protein blood level
quantitative analysis
rheumatoid arthritis
serum
systemic circulation
Aged
alpha-Macroglobulins
Antirheumatic Agents
Arthritis, Rheumatoid
Biological Markers
C-Reactive Protein
Down-Regulation
Enzyme Inhibitors
Female
Humans
Isoxazoles
Male
Matrix Metalloproteinases
Methotrexate
Middle Aged
Multiprotein Complexes
Phenylalanine
Statistics, Nonparametric
Thiophenes
To reference this document use:
http://resolver.tudelft.nl/uuid:5600f049-2bd1-45b0-8f92-599f932454f4
DOI
https://doi.org/10.1136/ard.2006.067827
TNO identifier
240571
ISSN
0003-4967
Source
Annals of the Rheumatic Diseases, 67 (67), 128-130
Document type
article